PBYI - Puma Biotechnology: Finding Bullish Indications At The End Of 2019

Puma Biotechnology (PBYI) reported $53.5M in product revenue for the third quarter of 2019, which was a 0.6% decline from the $53.8M in Q2. I was expecting an evisceration of the share price and strong tax-selling event leaving 2019. Remarkably, the market eventually found some positive notes and the stock ascended off its 52-week lows. Recently, PBYI has been trading sideways into 2020 but I believe this is a calm before the (positive) storm. After rereading the company’s ER and listening to the earnings call, I have found some bullish indicators for Puma